Ir.cytokinetics.com

Investors & Media

WebTreatment with Aficamten Associated with Significant Improvements in Symptoms and Quality of Life. Additional Data Presented in Poster Session Shows …

Actived: 5 days ago

URL: https://ir.cytokinetics.com/news-releases/news-release-details/cytokinetics-presents-new-data-redwood-hcm-ole-late-breaking-0

Cytokinetics Announces Upcoming Presentations at the 2022 …

WebTwo Late Breaking Clinical Trials Sessions to Feature New Data from REDWOOD-HCM OLE. SOUTH SAN FRANCISCO, Calif., Sept. 26, 2022 (GLOBE …

Category: Health Go Health

Cytokinetics Announces New Data From FOREST-HCM to be …

WebSOUTH SAN FRANCISCO, Calif., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced an upcoming presentation …

Category: Health Go Health

Cytokinetics Announces Start of SEQUOIA-HCM, a Phase 3 Clinical …

WebPivotal Trial to Assess the Potential of Aficamten to Improve Exercise Capacity, Heart Failure Symptoms and Functional Class SOUTH SAN FRANCISCO, …

Category: Health Go Health

Cytokinetics Provides Update on Cardiac Myosin Inhibitor …

WebCytokinetics scientists and collaborators are committed to high scientific and ethical publications standards and are dedicated to providing our science to the medical …

Category: Medical Go Health

Cytokinetics to Present at the 42nd Annual J.P. Morgan Healthcare

WebSOUTH SAN FRANCISCO, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, …

Category: Health Go Health

Cytokinetics Announces Upcoming Presentations at the 2023 …

WebBaseline Characteristics from SEQUOIA-HCM to be Presented at HCMS Scientific Sessions on October 6, 2023. SOUTH SAN FRANCISCO, Calif., Oct. 02, 2023 …

Category: Health Go Health

Investors & Media

WebCytokinetics scientists and collaborators are committed to high scientific and ethical publications standards and are dedicated to providing our science to the medical …

Category: Medical Go Health

Cytokinetics Announces Start of ACACIA-HCM, a Pivotal Phase 3 …

WebCytokinetics scientists and collaborators are committed to high scientific and ethical publications standards and are dedicated to providing our science to the medical …

Category: Medical Go Health

Press Releases Cytokinetics, Inc.

WebPress Releases. Press Release Archive 1998-2005. Year. 2024. Apr. 29. 2024. Cytokinetics to Host Investor Event and Conference Call to Discuss the Primary Results From SEQUOIA-HCM at the European Society of …

Category: Health Go Health

Cytokinetics Announces Preclinical Data for CK-3773274 Presented …

WebNext-In-Class Cardiac Myosin Inhibitor Optimized for Shallow Exposure Response and Pharmacokinetics to Enable Flexible Dose Titration. SOUTH SAN …

Category: Health Go Health

Cytokinetics, The Mended Hearts, Inc. and WomenHeart Announce …

WebCytokinetics scientists and collaborators are committed to high scientific and ethical publications standards and are dedicated to providing our science to the medical …

Category: Medical Go Health

Cytokinetics Announces Preclinical Data for CK-3773274 Presented …

WebSOUTH SAN FRANCISCO, Calif., July 31, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that preclinical data for CK …

Category: Health Go Health

Cytokinetics Presents Baseline Characteristics From SEQUOIA …

WebTopline Results from SEQUOIA-HCM Expected by End of Year. SOUTH SAN FRANCISCO, Calif., Oct. 06, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated …

Category: Health Go Health

Cytokinetics to Participate in the 23rd Annual Needham Virtual

WebSOUTH SAN FRANCISCO, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, …

Category: Health Go Health

Investors & Media

WebAnalysis Shows Treatment Effect of Omecamtiv Mecarbil Increased Progressively as Baseline Ejection Fraction Decreased. SOUTH SAN FRANCISCO, …

Category: Health Go Health

Amgen and Cytokinetics Announce Late-Breaking Presentation …

WebThe expansion phase of COSMIC-HF was designed to evaluate the pharmacokinetics, pharmacodynamics, safety and tolerability of oral omecamtiv mecarbil in 448 patients with chronic heart failure and left ventricular systolic dysfunction. Patients were randomized 1:1:1 to receive either placebo or treatment with omecamtiv mecarbil 25 mg …

Category: Health Go Health

Cytokinetics Announces Positive Results From SEQUOIA-HCM, the …

WebCytokinetics scientists and collaborators are committed to high scientific and ethical publications standards and are dedicated to providing our science to the medical …

Category: Medical Go Health

Cytokinetics Presents Additional 48-Week Data From FOREST …

WebCytokinetics scientists and collaborators are committed to high scientific and ethical publications standards and are dedicated to providing our science to the medical …

Category: Medical Go Health